Nothing Special   »   [go: up one dir, main page]

FR2943669B1 - Derives de nicotinamide,leur preparation et leur application en therapeutique - Google Patents

Derives de nicotinamide,leur preparation et leur application en therapeutique

Info

Publication number
FR2943669B1
FR2943669B1 FR0901365A FR0901365A FR2943669B1 FR 2943669 B1 FR2943669 B1 FR 2943669B1 FR 0901365 A FR0901365 A FR 0901365A FR 0901365 A FR0901365 A FR 0901365A FR 2943669 B1 FR2943669 B1 FR 2943669B1
Authority
FR
France
Prior art keywords
preparation
therapeutic application
nicotinamide derivatives
nicotinamide
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0901365A
Other languages
English (en)
Other versions
FR2943669A1 (fr
Inventor
Claude Bernhardt
Jerome Arigon
Monsif Bouaboula
Jerome Combet
Sandrine Hilairet
Samir Jegham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0901365A priority Critical patent/FR2943669B1/fr
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to RU2011142753/04A priority patent/RU2011142753A/ru
Priority to KR1020117024865A priority patent/KR20110133049A/ko
Priority to PCT/FR2010/050511 priority patent/WO2010109122A1/fr
Priority to EP10716566A priority patent/EP2411368A1/fr
Priority to BRPI1013553A priority patent/BRPI1013553A2/pt
Priority to CN2010800227689A priority patent/CN102448939A/zh
Priority to MX2011010052A priority patent/MX2011010052A/es
Priority to US13/258,220 priority patent/US20120053170A1/en
Priority to CA2756099A priority patent/CA2756099A1/fr
Priority to AU2010227402A priority patent/AU2010227402A1/en
Priority to SG2011068871A priority patent/SG174902A1/en
Priority to JP2012501349A priority patent/JP2012521396A/ja
Priority to ARP100100920A priority patent/AR075920A1/es
Priority to TW099108544A priority patent/TW201038554A/zh
Priority to UY0001032517A priority patent/UY32517A/es
Publication of FR2943669A1 publication Critical patent/FR2943669A1/fr
Application granted granted Critical
Publication of FR2943669B1 publication Critical patent/FR2943669B1/fr
Priority to IL215285A priority patent/IL215285A0/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR0901365A 2009-03-24 2009-03-24 Derives de nicotinamide,leur preparation et leur application en therapeutique Expired - Fee Related FR2943669B1 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
FR0901365A FR2943669B1 (fr) 2009-03-24 2009-03-24 Derives de nicotinamide,leur preparation et leur application en therapeutique
JP2012501349A JP2012521396A (ja) 2009-03-24 2010-03-22 ニコチンアミド誘導体、この調製および抗癌薬としてのこの治療的使用
PCT/FR2010/050511 WO2010109122A1 (fr) 2009-03-24 2010-03-22 Derives de nicotinamide, leur preparation et leur application en therapeutique comme anticancereux
EP10716566A EP2411368A1 (fr) 2009-03-24 2010-03-22 Derives de nicotinamide, leur preparation et leur application en therapeutique comme anticancereux
BRPI1013553A BRPI1013553A2 (pt) 2009-03-24 2010-03-22 derivados de nicotinamida, o respectivo preparo e a respectiva aplicação em terapêutica como anticancerígenos
CN2010800227689A CN102448939A (zh) 2009-03-24 2010-03-22 烟酰胺衍生物、其制备以及其作为抗癌药物的治疗用途
MX2011010052A MX2011010052A (es) 2009-03-24 2010-03-22 Derivados de nicotinamida, su preparación y su uso en terapéutica como agentes anticancerígenos.
US13/258,220 US20120053170A1 (en) 2009-03-24 2010-03-22 Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs
RU2011142753/04A RU2011142753A (ru) 2009-03-24 2010-03-22 Производные никотинамида, способ их получения и применение в терапии в качестве противораковых агентов
AU2010227402A AU2010227402A1 (en) 2009-03-24 2010-03-22 Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs
SG2011068871A SG174902A1 (en) 2009-03-24 2010-03-22 Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs
KR1020117024865A KR20110133049A (ko) 2009-03-24 2010-03-22 항암 약물로서의 니코틴아미드 유도체, 그의 제조법 및 그의 치료 용도
CA2756099A CA2756099A1 (fr) 2009-03-24 2010-03-22 Derives de nicotinamide, leur preparation et leur application en therapeutique comme anticancereux
ARP100100920A AR075920A1 (es) 2009-03-24 2010-03-23 Derivados de nicotinamida su preparacion y su aplicacion en terapeutica
TW099108544A TW201038554A (en) 2009-03-24 2010-03-23 Nicotinamide derivatives, their preparation and their therapeutic application
UY0001032517A UY32517A (es) 2009-03-24 2010-03-24 Derivados de nicotinamida, su preparación y su aplicación en terapéutica
IL215285A IL215285A0 (en) 2009-03-24 2011-09-21 Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0901365A FR2943669B1 (fr) 2009-03-24 2009-03-24 Derives de nicotinamide,leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
FR2943669A1 FR2943669A1 (fr) 2010-10-01
FR2943669B1 true FR2943669B1 (fr) 2011-05-06

Family

ID=40792887

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0901365A Expired - Fee Related FR2943669B1 (fr) 2009-03-24 2009-03-24 Derives de nicotinamide,leur preparation et leur application en therapeutique

Country Status (17)

Country Link
US (1) US20120053170A1 (fr)
EP (1) EP2411368A1 (fr)
JP (1) JP2012521396A (fr)
KR (1) KR20110133049A (fr)
CN (1) CN102448939A (fr)
AR (1) AR075920A1 (fr)
AU (1) AU2010227402A1 (fr)
BR (1) BRPI1013553A2 (fr)
CA (1) CA2756099A1 (fr)
FR (1) FR2943669B1 (fr)
IL (1) IL215285A0 (fr)
MX (1) MX2011010052A (fr)
RU (1) RU2011142753A (fr)
SG (1) SG174902A1 (fr)
TW (1) TW201038554A (fr)
UY (1) UY32517A (fr)
WO (1) WO2010109122A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106986856A (zh) 2010-09-03 2017-07-28 福马Tm有限责任公司 作为用于治疗疾病诸如癌症的nampt抑制剂的4‑{[(吡啶‑3‑基‑甲基)氨基羰基]氨基}苯‑砜衍生物
RU2617988C2 (ru) 2010-09-03 2017-05-02 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
KR20140027366A (ko) 2011-05-04 2014-03-06 포르마 티엠, 엘엘씨. Nampt의 억제를 위한 신규 화합물 및 조성물
JP2014518223A (ja) * 2011-06-20 2014-07-28 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド 化合物とその治療用途
EP2712862A1 (fr) 2012-09-28 2014-04-02 Splicos Nouveaux composés anti-invasifs
EP2925750A1 (fr) 2012-11-29 2015-10-07 Karyopharm Therapeutics, Inc. Composés 2,3-dihydrobenzofuranyle substitués et leurs utilisations
SG11201510339UA (en) 2013-07-03 2016-01-28 Karyopharm Therapeutics Inc Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
WO2015042414A1 (fr) 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Composés multicycliques et leurs procédés d'utilisation
DK3302435T3 (da) * 2015-05-26 2023-06-06 Plumb Pharmaceuticals Inc Liposomladning
AU2016308829A1 (en) 2015-08-18 2018-03-08 Karyopharm Therapeutics Inc. (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
WO2017117447A1 (fr) * 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Composés multicycliques et leurs utilisations
WO2023119230A1 (fr) 2021-12-22 2023-06-29 L'oreal Compositions de modulation de la voie de coagulation et de la voie de nicotinamide-adénine dinucléotide et leurs procédés d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327734D0 (en) * 2003-11-28 2003-12-31 Novartis Ag Organic compounds
AU2004292773A1 (en) * 2003-11-28 2005-06-09 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
KR20200019263A (ko) * 2004-09-02 2020-02-21 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
UY32517A (es) 2010-10-29
WO2010109122A1 (fr) 2010-09-30
MX2011010052A (es) 2012-01-12
EP2411368A1 (fr) 2012-02-01
CA2756099A1 (fr) 2010-09-30
TW201038554A (en) 2010-11-01
CN102448939A (zh) 2012-05-09
US20120053170A1 (en) 2012-03-01
KR20110133049A (ko) 2011-12-09
AR075920A1 (es) 2011-05-04
IL215285A0 (en) 2011-11-30
AU2010227402A1 (en) 2011-10-20
JP2012521396A (ja) 2012-09-13
RU2011142753A (ru) 2013-04-27
BRPI1013553A2 (pt) 2016-04-12
FR2943669A1 (fr) 2010-10-01
SG174902A1 (en) 2011-11-28

Similar Documents

Publication Publication Date Title
FR2949470B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
FR2953520B1 (fr) Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
FR2943669B1 (fr) Derives de nicotinamide,leur preparation et leur application en therapeutique
FR2933700B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2963007B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
FR2945534B1 (fr) DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2926556B1 (fr) Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2915198B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
FR2952934B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2928924B1 (fr) Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2911604B1 (fr) Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2915199B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
FR2915197B1 (fr) Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
FR2948939B1 (fr) Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine
FR2917413B1 (fr) Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2954943B1 (fr) Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
FR2927625B1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2947546B1 (fr) Derives de pyrazoles, leur preparation et leur application en therapeutique
FR2940284B1 (fr) Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2932481B1 (fr) Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2925901B1 (fr) DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2986232B1 (fr) Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique
FR2967672B1 (fr) Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
FR2930939B1 (fr) Derives de pyrrole, leur preparation et leur application en therapeutique
FR2911605B1 (fr) Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20131129